TABLE 1.
Univariate and multivariate analysis for recurrence free survival of cytoplasmic CAIX protein expression and clinicopathological characteristics in ER‐negative cohort (n = 191).
| Clinicopathological characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (≤ 50/> 50 years) | 0.98 (0.58–1.66) | 0.943 | — | — |
| Tumour size (mm) (≤ 20/21–50/> 50) | 2.25 (1.45–3.51) | < 0.001* | 1.67 (0.84–3.33) | 0.146 |
| Grade (I/II/III) | 1.62 (0.87–3.02) | 0.131 | — | — |
| Involved lymph node (negative/positive) | 2.84 (1.64–4.91) | < 0.001* | 2.17 (0.94–5.01) | 0.071 |
| PR status (negative/positive) | 0.43 (0.06–3.08) | 0.397 | — | — |
| Her‐2 status (negative/positive) | 1.20 (0.69–2.07) | 0.508 | — | — |
| Ki67 index (low/high) | 1.04 (0.59–1.81) | 0.903 | — | — |
| Lymphatic vessel invasion (no/yes) | 4.04 (2.07–7.89) | < 0.001* | 2.28 (1.00–5.18) | 0.049* |
| Blood vessel invasion (no/yes) | 2.76 (1.29–5.88) | 0.009* | 1.21 (0.49–2.99) | 0.683 |
| Tumour necrosis (low/high) | 3.35 (1.34–8.38) | 0.010* | 8.99 (1.21–66.63) | 0.032* |
| Klintrup–Mäkinen grade (low/high) | 0.80 (0.56–1.15) | 0.228 | — | — |
| CD68+ (low/moderate/high) | 0.69 (0.47–1.03) | 0.071 | — | — |
| CD8+ (low/moderate/high) | 0.59 (0.39–0.86) | 0.007* | 0.83 (0.53–1.30) | 0.410 |
| CD138+ (low/moderate/high) | 1.31 (0.90–1.89) | 0.159 | — | — |
| Tumour stroma percentage (low/high) | 2.43 (1.45–4.07) | < 0.001* | 3.63 (1.75–7.55) | < 0.001* |
| Tumour budding (low/high) | 2.53 (1.49–4.31) | < 0.001* | 1.09 (0.46–2.55) | 0.846 |
| Adjuvant chemotherapy (no/yes) | 1.40 (0.79–2.49) | 0.249 | — | — |
| Adjuvant radiotherapy (no/yes) | 1.50 (0.88–2.57) | 0.136 | — | — |
| Cytoplasmic CAIX (low/high) | 1.84 (1.09–3.09) | 0.019* | 2.34 (1.15–4.76) | 0.019* |
Abbreviations: Lum A, Luminal A; Lum B, Luminal B.
*
p < 0.05.